This site is intended for
U.S. healthcare professionals
Enrollment and Prescription Form Available Soon
The Enrollment and Prescription Form is not yet available.
Please check back to download the latest form.
Return to previous pageSUPPORT PROGRAMS
Once You’ve Decided to Prescribe OPSYNVI® (macitentan/tadalafil)
Janssen Has the Demonstrated Expertise and Support Programs to Help Your Patients ACCESS, START, and STAY on Therapy
ACCESS to Therapy
Insurance Can Feel Burdensome. Janssen Can Help You Navigate the Approval Process
When you enroll patients through Janssen CarePath:
- Janssen CarePath Care Coordinators will conduct a benefits investigation and help you navigate the approval process
- Patients will be able to enroll in Janssen-sponsored support programs
Our TAMs are here to provide education and assistance throughout the payer approval and patient access processes to help your patients access, start, and stay on their prescribed Janssen PAH therapy.
START on Therapy
Janssen Believes That Cost, Coverage, and Uncertainty Shouldn’t Stand in the Way of Patients and Their Medications
OPSYNVI® (macitentan/tadalafil) Voucher Program
A free trial offer is available for eligible patients to help them become familiar with OPSYNVI®.
At the conclusion of the program, you and your patient decide whether to continue treatment.
Subject to one (1) use per lifetime for the patient’s first trial of OPSYNVI®. Terms expire at the end of each calendar year and may change. This Voucher Program is open to patients who have commercial insurance, government coverage, or no insurance coverage; however, there is no guarantee of continuous accessibility after the program ends.
Janssen CarePath Oral PAH Saving Program
Once you've decided to prescribe a Janssen PAH therapy, support for patients using commercial or private insurance to pay for medication is available. Janssen CarePath Oral PAH Savings Program can help eligible patients save on their out-of-pocket costs for their Janssen medication. Your eligible patients will pay $5 per prescription fill for OPSYNVI® (macitentan/tadalafil). Maximum program benefit per calendar year shall apply across all oral PAH therapies in the program. Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change.
Once a decision has been made to prescribe a Janssen PAH medication, Janssen CarePath can provide information about other resources that may be able to help your patients with their out-of-pocket medication costs. Visit JanssenCarePath.com for more information on affordability programs that may be available.
Janssen Patient Assistance Program
Patient assistance is available if your patient has commercial, employer-sponsored, or government coverage that does not fully meet their needs. Your patient may be eligible to receive their Janssen medication free of charge for up to one year if they meet the eligibility and income requirements for the Janssen Patient Assistance Program. See terms and conditions at PatientAssistanceInfoPH.com.
Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF)
The Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is an independent, nonprofit organization. JJPAF helps eligible patients get free prescription medicines donated by Johnson & Johnson companies. Patients may be eligible if they don’t have insurance.
Do you have patients who may need help? They can see if they are eligible and get an application at JJPAF.org or call 833-919-3510833-919-3510 (toll free) / 308-920-4358308-920-4358 (direct dial), Monday through Friday, 8:00 AM to 8:00 PM ET.
STAY on Therapy
We Offer Patients One-on-One Educational Support That May Help Them Stay on Their Prescribed Therapy Longer1,2*
Once a decision has been made to prescribe a Janssen PAH medication, PAH Companion withMe† is a suite of patient support resources customized for your patients’ specific questions, needs, and interests. One-on-one educational conversations with a dedicated PAH Companion—coupled with access to current PAH tools and resources—help your patients take a more active role in their care. Learn more at PAHcompanion.com
DID YOU KNOW?
Over 10,000 patients have engaged with a dedicated PAH Companion, and those who do are more likely to stay on therapy longer. Ninety-four percent of patients who have enrolled and engaged with a dedicated PAH Companion would recommend the program to others.3,4
A dedicated PAH Companion is ready to answer your patients’ questions and help them navigate their treatment experience. Patients who have enrolled can connect with their personal PAH Companion by calling 866-300-1818, Monday–Friday, 8:00 AM to 9:00 PM ET.
PAH Companion withMe is limited to education for patients about their PAH therapy, its administration, and/or their disease, and is not intended to provide medical advice, replace a treatment plan from the patient’s doctor or nurse, or provide case management services.
*
Based on 120-day persistency as of Q1 2023.
†
PAH Companion withMe requires a completed patient authorization form to enroll.
Science Liaison (MSL)Contact your MSL
Enrollment and Prescription Form Available Soon
The Enrollment and Prescription Form is not yet available.
Please check back to download the latest form.
Return to previous pagePA=prior authorization; PAH=pulmonary arterial hypertension.
References: 1. Data on file. Actelion Pharmaceuticals US, Inc. Janssen Insights and Analytics Team. September 2023. 2. Data on file. UPTRAVI® Nurse Support Program Patient Persistency Data, Onboarding Dashboard Q1 2023. October 2023.
3. Data on File. Actelion Pharmaceuticals US, Inc. Janssen. PAHC Patient Survey Data. April 2023. 4. Data on File. Actelion Pharmaceuticals US, Inc. Janssen. PAHC Patients Engaged. September 2023.
